title: Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr.
abstract: The metabolic syndrome is a group of disorders including obesity, insulin resistance, atherogenic dyslipidemia, hyperglycemia, and hypertension. To date, few animal models have been described to recapitulate the phenotypes of the syndrome. In this study, we generated and characterized two lines of triple-knockout mice that are deficient in either apolipoprotein E (Apoe(-/-)) or low-density lipoprotein receptor (Ldlr(-/-)) and express no leptin (Lep(ob/ob)) or apolipoprotein B-48 but exclusively apolipoprotein B-100 (Apob(100/100)). These two lines are referred to as Apoe triple-knockout-Apoe 3KO (Apoe(-/-)Apob(100/100)Lep(ob/ob)) and Ldlr triple-knockout-Ldlr 3KO (Ldlr(-/-)Apob(100/100)Lep(ob/ob)) mice. Both lines develop obesity, hyperinsulinemia, hyperlipidemia, hypertension, and atherosclerosis. However, only Apoe 3KO mice are hyperglycemic and glucose intolerant and are more obese than Ldlr 3KO mice. To evaluate the utility of these lines as pharmacological models, we treated both with leptin and found that leptin therapy ameliorated most metabolic derangements. Leptin was more effective in improving glucose tolerance in Ldlr 3KO than Apoe 3KO animals. The reduction of plasma cholesterol by leptin in Ldlr 3KO mice can be accounted for by its suppressive effect on food intake. However, in Apoe 3KO mice, leptin further reduced plasma cholesterol independently of its effect on food intake, and this improvement correlated with a smaller plaque lesion area. These effects suggest a direct role of leptin in modulating VLDL levels and, likewise, the lesion areas in VLDL-enriched animals. These two lines of mice represent new models with features of the metabolic syndrome and will be useful in testing therapies targeted for combating the human condition.
authors.affiliation: Department of Metabolic Disorders, Amgen Incorporated, Thousand Oaks, California 91320, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Lloyd
authors.forename: Jocelyn
authors.initials: J
authors.lastname: McCormick
authors.forename: Joan
authors.initials: J
authors.lastname: Helmering
authors.forename: Ki Won
authors.initials: KW
authors.lastname: Kim
authors.forename: Minghan
authors.initials: M
authors.lastname: Wang
authors.forename: Preston
authors.initials: P
authors.lastname: Fordstrom
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Kaufman
authors.forename: Richard A
authors.initials: RA
authors.lastname: Lindberg
authors.forename: Murielle M
authors.initials: MM
authors.lastname: Véniant
mesh_terms: D000818:Animals; D053283:Apolipoprotein B-48 / Q000172:deficiency*; D001057:Apolipoproteins E / Q000172:deficiency*; D004195:Disease Models, Animal; D006943:Hyperglycemia; D006949:Hyperlipidemias; D006973:Hypertension; D007333:Insulin Resistance; D020738:Leptin / Q000008:administration & dosage / Q000172:deficiency*; D008079:Lipoproteins, VLDL / Q000008:administration & dosage; D008297:Male; D024821:Metabolic Syndrome; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009765:Obesity; D010641:Phenotype; D011973:Receptors, LDL / Q000172:deficiency*
chemical_list: D053283:Apolipoprotein B-48; D001057:Apolipoproteins E; D020738:Leptin; D008079:Lipoproteins, VLDL; D011973:Receptors, LDL